Allogene rises as FDA offers Fast Track, RMAT tags to cell therapy
Allogene saw an upward trend after receiving Fast Track and RMAT (Regenerative Medicine Advanced Therapy) designation from the FDA for its cell therapy product.
Given the strong positive catalyst of FDA Fast Track and RMAT designation, with the reference price (closing price 2.01) as of 2026-08-07 situated near the resistance level of 2.00, I see potential for a resistance break on further momentum and will consider entering.
With the momentum from the RMAT designation, if it breaks above the resistance level of 2.00 and the uptrend continues, we expect to reach the profit‑taking target of $2.25. Conversely, if it faces downward pressure and the support level around 1.65 breaks, we will manage risk at the stop‑loss level of $1.55.
Based on the strong positive catalyst of the FDA's Fast Track and RMAT designations, we anticipated a breakout near the resistance level of $2.00; the actual outcome delivered a 10.8% return, earning a SUCCESS rating. Although there was a slight variance between the projected return of 12.0% and the actual result, the price held firmly above the support level of $1.65 despite the risk of a pullback after the rally, advancing toward the target price in a manner consistent with the prior candlestick and momentum analysis.
Through this trade, we confirmed that when accompanied by strong policy catalysts (RMAT, Fast Track), attempts to break through resistance levels are valid. However, if the overall news‑count trend for the theme is in a declining (falling) phase, the stock may experience residual volatility during the process of reaching the target price; therefore, in similar entry scenarios going forward, we will apply a more granular profit‑taking strategy to reduce the discrepancy between forecasts and actual outcomes.